Balyasny Asset Management L.P. boosted its position in shares of Relx Plc (NYSE:RELX - Free Report) by 32.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 58,235 shares of the technology company's stock after purchasing an additional 14,327 shares during the period. Balyasny Asset Management L.P.'s holdings in Relx were worth $2,645,000 as of its most recent SEC filing.
Several other hedge funds also recently added to or reduced their stakes in the company. Bank of America Corp DE grew its stake in Relx by 4.2% in the 4th quarter. Bank of America Corp DE now owns 6,246,462 shares of the technology company's stock worth $283,714,000 after acquiring an additional 253,107 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Relx by 4.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,189,886 shares of the technology company's stock worth $144,885,000 after purchasing an additional 121,831 shares during the period. Ameriprise Financial Inc. lifted its position in Relx by 368.7% during the fourth quarter. Ameriprise Financial Inc. now owns 2,807,038 shares of the technology company's stock valued at $127,437,000 after acquiring an additional 2,208,119 shares during the last quarter. Northern Trust Corp lifted its position in Relx by 51.6% during the fourth quarter. Northern Trust Corp now owns 2,191,588 shares of the technology company's stock valued at $99,542,000 after acquiring an additional 745,532 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its stake in Relx by 50.3% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,968,739 shares of the technology company's stock valued at $89,420,000 after purchasing an additional 658,655 shares in the last quarter. 15.02% of the stock is currently owned by institutional investors.
Relx Price Performance
Shares of Relx stock traded up $0.62 during mid-day trading on Wednesday, reaching $53.02. 562,924 shares of the stock traded hands, compared to its average volume of 710,617. The stock has a market capitalization of $98.13 billion, a PE ratio of 28.51, a PEG ratio of 2.73 and a beta of 0.86. The business has a 50-day moving average of $50.76 and a 200 day moving average of $48.77. Relx Plc has a fifty-two week low of $43.28 and a fifty-two week high of $55.21. The company has a quick ratio of 0.47, a current ratio of 0.52 and a debt-to-equity ratio of 1.46.
Relx Increases Dividend
The company also recently disclosed a semi-annual dividend, which will be paid on Wednesday, June 25th. Investors of record on Friday, May 9th will be paid a $0.5586 dividend. This is an increase from Relx's previous semi-annual dividend of $0.23. This represents a yield of 1.6%. The ex-dividend date of this dividend is Friday, May 9th. Relx's dividend payout ratio is currently 59.68%.
Analyst Ratings Changes
RELX has been the subject of a number of analyst reports. Morgan Stanley reiterated an "overweight" rating on shares of Relx in a research report on Wednesday, April 16th. Barclays upgraded Relx from an "equal weight" rating to an "overweight" rating in a research report on Friday, March 14th. The Goldman Sachs Group initiated coverage on Relx in a research note on Wednesday, March 26th. They set a "buy" rating for the company. Finally, StockNews.com lowered shares of Relx from a "buy" rating to a "hold" rating in a report on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Relx currently has a consensus rating of "Buy".
Check Out Our Latest Stock Analysis on RELX
About Relx
(
Free Report)
RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.
Recommended Stories
Before you consider Relx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relx wasn't on the list.
While Relx currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
